With Accenture predicting that AI in healthcare could save the US healthcare economy $150 billion dollars, there is no wonder that this has engaged substantial technological growth within the sector in recent years. 

AI application within drug development and its focus on primary drug discovery remains firmly within its infancy. 

So, as a starting point, how do we understand the real implications and value of AI in primary drug discovery? We’ve turned to expert Jackie Hunter, Board Director of bioscience division BenevolentAI, to pinpoint the fundamentals here.